GlassScriptPhysician profile
Heidi Rezendes
NPI 1447503081
$6,229.73
in general payments reported to CMS, 2019-2025
24 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $591 · 2023: $1,792 · 2024: $2,292 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,305 · Education: $73.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,305.03 |
| Education | $73.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,478.51 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $652.54 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $412.79 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $412.48 | 2023-2025 | |
| Gilead Sciences, INC. | $331.97 | 2021-2025 | Livdelzi |
| Ardelyx, INC. | $264.25 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $230.31 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $189.57 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $181.58 | 2021-2023 | |
| Pfizer INC. | $155.90 | 2023-2024 | |
| Madrigal Pharmaceuticals | $131.24 | 2024-2025 | Rezdiffra |
| Lilly USA, LLC | $119.75 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $117.49 | 2024-2025 | Dupixent |
| Intuitive Surgical, INC. | $98.48 | 2023 | Da Vinci Surgical System |
| E.R. Squibb & Sons, L.L.C. | $83.20 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $79.77 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $68.74 | 2022-2025 | |
| Celgene Corporation | $64.82 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $34.99 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $31.52 | 2022-2023 | Dificid |
| Aimmune Therapeutics, INC. | $28.94 | 2024 | |
| Celltrion USA INC. | $22.94 | 2023 | Yuflyma |
| Organon LLC | $19.34 | 2023 | Renflexis |
| Shield Therapeutics INC | $18.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Rezendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.